EditorialKommentar
Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression
NEJM Evidence · 2024
DOI: 10.1056/evide2400205 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM Evidence, 2024. Verfasst von Paolo S Silva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Disease Progression, Fenofibrate, Hypolipidemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Diabetic RetinopathyDisease ProgressionFenofibrateHypolipidemic AgentsHumans
Substanzen
FenofibrateHypolipidemic Agents
Autor:innen und Institutionen
- Department of Ophthalmology, Harvard Medical School, Boston.
- Beetham Eye Institute, Joslin Diabetes Center, Boston.
Zitieren
APA
Silva, P. S., & Aiello, L. P. (2024). Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression. NEJM Evidence. https://doi.org/10.1056/evide2400205
Vancouver
Silva PS, Aiello LP. Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression. NEJM Evidence. 2024. doi:10.1056/evide2400205
BibTeX
@article{Silva2024,
author = {Silva, Paolo S and Aiello, Lloyd Paul},
title = {Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression},
journal = {NEJM Evidence},
year = {2024},
doi = {10.1056/evide2400205}
}
EUVIMED